EQx Fund
VC Fund
Boston, United States
EQx Fund is a VC fund in Boston focused on Health Care and Biotechnology. EQx Fund operates an angel investment fund focusing on diversified early stage investments in extraordinary founders. EQx Fund seeks the founders and leaders that can grow the business and take a company from idea to exit, and invest early on in the Seed to Series A round.The fund is industry agnostic and follows an evergreen structure, allowingnew investors to join at any point for the opportunity to participate in the next 20 deals.EQx Fund is headquartered in Boston, Massachusetts.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries EQx Fund invests in
Stages EQx Fund invests in
Countries EQx Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jason Kraus
|
|||
Ziad H. Moukheiber
|
|||
Investment Focus
Industry
- Health Care 9 (45%)
- Biotechnology 7 (35%)
- Medical 4 (20%)
- Pharmaceutical 3 (15%)
- FinTech 2 (10%)
Stage
- Seed 8 (40%)
- Convertible Note 5 (25%)
- Pre-Seed 2 (10%)
- Series A 2 (10%)
- Series B 2 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jason Kraus
Partner
|
Partner | Total investments: 0 | Find email | |
|
Ziad H. Moukheiber
Managing Partner
|
Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Winter Innovations
|
Winter Innovations is developing medical devices that can improve outcomes for patients who have suffered from orthopedic injuries. The startup working to launch EasyWhip, a patent-pending suturing needle intended to be used for orthopedic ligament and tendon reconstruction surgery.The company was founded in 2018 and is headquartered inKnoxville, TN. | Pre-Seed / Jun 16, 2021 | |
S'More Date
|
S'More Date they provide daters with a totally interactive way to learn more about a person before evaluating them on appearance. | $2.1M / Seed / Jan 26, 2021 | |
Gelmedix
|
Gelmedix is a developer of a biomaterial platform to improve drug delivery for complicated ophthalmic treatment. The company's platform offers a single non-invasive gel patch that can be used as a drug-eluting sealant with tissue adhesion, tunable drug elution, and biocompatibility properties, thereby enabling healthcare providers to reducethe usage of drops which cause inconvenience to patients. | Convertible Note / Jun 04, 2020 | |
Dressbarn
|
Born in 1962, Dressbarn has grown into a trusted brand known and loved for its great sense of family and unwavering customer service. With style and size options for all types of women, Dressbarn prides itself on its selection, service and price. For almost 60 years, Dressbarn has consistently partnered with familiar brands that provide the trustedstyles consumers love. Traditionally recognized as the go-to store for wear-to-work styles, Dressbarn has kept to its original promise while also expanding into affordable loungewear, everyday wear and jewelry. To learn more, please visit dressbarn.com, download the Dressbarn app. | Seed / May 04, 2020 | |
CytoAgents
|
CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation also known as cytokine storm. | Convertible Note / Apr 30, 2020 | |
Archer Roose
|
Archer Roose is a clean wine brand cultivating a new generation of consumers through a global portfolio and a tech platform making wine more accessible than ever before. | Convertible Note / Apr 20, 2020 | |
Quthero
|
Accelerating the ways we treat wounds today - from passive to rapid, & healthy wound management | Seed / Mar 21, 2020 | |
Anubis Bio
|
Anubis Bio has USPTO patented Microbiome-Cleanser (TM) natural food platform that quickly resolves GI-distress-diarrhea in animals starting with dogs (www.doggystat.com). Two major B2B distribution partnerships signed in 2021. | Seed / Jun 07, 2019 | |
Platelet BioGenesis
|
Platelet BioGenesis specializes in the fields of biotechnology, platelets, and drug discovery. They discover a new category in therapeutics. The company is developing technology to produce donor-independent human platelets from human induced pluripotent stem cells. | Series A / May 31, 2019 | |
BrandVerge
|
BrandVerge is a marketplace + workflow tool that makes it easy for advertisers to plan premium media partnerships at scale. Our platform takes brands from discovery to recommendation in a few easy steps, ultimately bringing relevant buyers to the media companies on BrandVerge! We are the only two-sided solution in the space that proactivelyincreases visibility and new business for our publisher partners, while simultaneously increasing efficiency for our advertisers by 80+%. | Convertible Note / May 03, 2019 | |
| See all 20 investments → | |||
Co-Investors
Boston Harbor Angels
2 deals together
Gaingels
2 deals together
Sidecar Angels
2 deals together
600 Mile Challenge Fund
1 deal together
Benson Oak Ventures
1 deal together
Colony Hills Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does EQx Fund invest in?
EQx Fund invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Convertible Note stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact EQx Fund?
Public channels for EQx Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at EQx Fund?
The team at EQx Fund includes Jason Kraus (Partner) and Ziad H. Moukheiber (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
